Study of Imatinib (Glivec) in Patients With Adenoid Cystic Carcinoma of the Head and Neck
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a Phase II study of imatinib (Glivec) administered as a daily oral treatment in
patients with recurrent/metastatic adenoid cystic carcinoma of the head and neck
overexpressing KIT.